ChAdOx1 nCoV-19

N/A

Report date: 2025/04/14 14:32:44

Base Information

Drug NameChAdOx1 nCoV-19
Drug Alias NameChAdOx1-SSII-ChAdOx1 nCoV-19Recombinant COVID-19 Vaccine (AstraZeneca)CovishieldVaxzevria +[7] 
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2020/12/30
Country/TerritoryBotswanaUnited StatesPoland +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesUniversity Of OxfordBarinthus Biotherapeutics PLC
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcHalix BVBotswana Harvard Aids Institute +[5] 
Inactive CompaniesFederal University Of Espirito SantoUniversity Of OxfordAstrazeneca Ab
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeJ07B
Related LinksN/A